Malcolm Pike, PhD

Attending Epidemiologist

Malcolm Pike, PhD

Attending Epidemiologist

Pictured: Malcolm Pike

Office Phone

646-888-8240

E-mail

pikem@mskcc.org

Current Research Interests

Dr. Pike’s research interests are in the etiology and chemoprevention of breast, endometrial and ovarian cancer.  A woman’s risks of endometrial cancer and of ovarian cancer are significantly and importantly reduced by use of oral contraceptives (OCs). The protection increases with increasing duration of OC use and lasts for more than 30 years after the last use of OCs. Why OC use protects against endometrial cancer is well-understood, but why OC use protects against ovarian cancer is not. Understanding the mechanism of prevention is important in order to guide research into how to increase the protective effect. For example, until recently almost all OC packs contained 21 active and 7 placebo pills, but recently a number of OCs have been marketed increasing the ratio of active to placebo pills to 24:4 and 84:7. If ovarian cancer risk reduction is determined through ovulation inhibition these changes will have little effect on the extent of risk reduction.  If, however, the protection is through increased exposure to the progestin component of the OC then these changes could make the protection much greater. Dr. Pike is working with gynecologic faculty at Memorial Sloan Kettering on understanding the mechanism of protection against ovarian cancer from OCs by studying the biology of the fallopian tube and cortical inclusion cysts within the ovary, the two sites where current evidence suggests most ovarian cancers arise.  Dr. Pike is also working with radiology faculty at Memorial Sloan Kettering to evaluate whether the various forms of breast magnetic resonance imaging (MRI) can be used to identify women at greatly increased risk of breast cancer and to study the ‘activity’ of the breast as an aid to various studies of possible approaches to prevention of breast cancer, including changes in OC formulation.

Education

Aberdeen University, Scotland

Publications

King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA.  Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011; 260:50-60. [PubMed Abstract]

Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL.  Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.  Breast Cancer Res Treat 2011 (Epub ahead of print).  [PubMed Abstract]

Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL.  Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception (in press).

Read more

  1. Pike MC. Some numerical results for the queueing system D/Ek/1. J Roy Stat Soc 1963; 25:477-485.

  2. Pike MC, Proctor DM, Wyllie JM. Analysis of admissions to a casualty ward. Br J Prev Soc Med 1963; 17:172-176.

  3. Pike MC, Roe FJC: An actuarial method of analysis of an experiment in two- stage carcinogenesis. Br J Cancer 1963; 17:605-610.

  4. White MJB, Pike MC: Appointment systems in out-patients’clinics and the effect of patients’ unpunctuality. Medical Care 1964; 2:133-143.

  5. Pike MC, Alper T: A method for determining dose-modification factors. Br J Radiol 1964; 37:458-462.

  6. Buckton KE, Pike MC: Chromosome investigations on lymphocytes from irradiated patients: effect of time in culture. Nature 1964; 202:714-715.

  7. Buckton KE, Pike MC: Time in culture: an important variable in studying in vivo radiation-induced chromosome damage in man. Int J Rad Biol 1964; 8:439-452.

  8. Pike MC, Doll R: Age at onset of lung cancer: significance in relation to effect of smoking. Lancet 1965; i:665-668.

  9. Pike MC: A method of analysis of a certain class of experiments in carcinogenesis. Biometrics 1966; 22:142-161.

  10. Grant G, Roe FJC, Pike MC: Effect of neonatal thymectomy on the induction of papillomata and carcinomata by 3,4-benzopyrene in mice. Nature 1966; 210:603-604.

  11. Medical Research Council (Pike MC, member of Working Group): Treatment of acute leukemia in adults: comparison of steroid and mercaptopurine therapy, alone and in conjunction. Br Med J 1966; i:1383-1389.

  12. Pike MC, Williams EH, Wright B: Burkitt’s tumor in the West Nile district of Uganda 1961-5. Br Med J 1967; ii:395-399.

  13. Garrow JS, Pike MC: The long-term prognosis of severe infantile malnutrition. Lancet 1967; i:1-4.

  14. Till MM, Hardisty RM, Pike MC, Doll R: Childhood leukemia in Greater London: a search for evidence of clustering. Br Med J 1967; iii:755-758.

  15. Garrow JS, Pike MC: The short-term prognosis of severe primary infantile malnutrition. Br J Nutr 1967; 21:155-165.

  16. Morrow RH, Pike MC, Kisuule A: Survival of Burkitt’s lymphoma patients in Mulago Hospital, Uganda. Br Med J 1967; iv:323-327.

  17. Pike MC, Smith PG: Disease clustering: a generalization of Knox’s approach to the detection of space-time interactions. Biometrics 1968; 24:541-556.

  18. Grant GA, Carter RL, Roe FJC, Pike MC: Effects of the neonatal injection of a carcinogen on the induction of tumors by the subsequent application to the skin of the same carcinogen. Br J Cancer 1968; 22:346-358.

  19. Medical Research Council (Pike MC, member of Working Group): Chronic granulocytic leukemia: comparison of radiotherapy and Busulphan therapy. Br Med J 1968; i:201-208.

  20. British Tuberculosis Association (Pike MC, member of Working Group): Treatment of house dust allergy. Br Med J 1968; iii:774-777.

  21. Arnhold RG, Pike MC: Patients and prescriptions: understanding medical instructions (a study in an East African dispensary). J Trop Paed 1968; 14:10-14.

  22. Williams EH, Spit P, Pike MC: Further evidence of space-time clustering of Burkitt’s lymphoma patients in the West Nile District of Uganda. Br J Cancer 1969; 23:235-246.

  23. Uganda Buruli Group (Pike MC, member of Working Group): BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer): first results of a trial in Uganda. Lancet 1969; i:111-115.

  24. Pike MC, Morrow RH: Statistical analysis of patient control studies in epidemiology. Br J Prev Soc Med 1970; 24:42-44.

  25. Pike MC, Morrow RH, Kisuule A, Mafigiri J: Burkitt’s lymphoma and sickle cell trait. Br J Prev Soc Med 1970; 24:39-41.

  26. Pike MC: A note on Kimball’s paper “Models for the estimation of competing risks from grouped data”. Biometrics 1970; 26:579-581.

  27. Juel-Jensen BE, MacCallum FO, MacKenzie AMR, Pike MC: Treatment of zoster with idoxuridine in dimethyl sulphoxide. Br Med J 1970; iv:776-780.

  28. Bagshawe G, Rawlings G, Pike MC, Lawler S: The ABO blood groups in trophoblastic neoplasia. Lancet 1971; i:553-556.

  29. Medical Research Council: Myelomatosis: comparison of melphelan and cyclophosphamide therapy. Br Med J 1971; i:640-641.

  30. Morrow RH, Pike MC, Smith PG, Ziegler JL, Kisuule A: Burkitt’s lymphoma: a time-space cluster of cases in Bwamba County of Uganda. Br Med J 1971; ii:491-492.

  31. Kinlen LJ, Pike MC: BCG vaccination and leukemia. Lancet 1971; ii:398- 402.

  32. Uganda Buruli Group: Epidemiology of mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Trans Roy Soc Trop Med Hyg 1971; 65:763-775.

  33. Medical Research Council (Pike MC, member of Working Group): Treatment of acute lymphoblastic leukemia: comparison of immunotherapy (BCG), intermittent methotrexate and no therapy after a 5-month intensive cytotoxic regime. Br Med J 1971; iv:189-194.

  34. Bobrow M, Pearson PL, Pike MC, E1-Alfi OS: Length variation in the quinacrine-binding segment of human Y chromosomes of different sizes. Cytogenetics 1971; 10:190-198.

  35. Medical Research Council (Pike MC, member of Working Group): Duration of survival of children with acute leukemia. Br Med J 1971; iv:7-9.

  36. Kafuko GW, Henderson BE, Kirya BG, Munube GMR, Tukei PM, Day NE, Henle G, Henle W, Morrow RH, Pike MC, Smith PG, Williams EH: Epstein-Barr virus antibody levels in children from the West Nile District of Uganda. Lancet 1972; i:706-709.

  37. Doll R, Pike MC: Trends in mortality among British doctors in relation to their smoking habits. J Roy Coll Phyns London 1972; 6:216-222.

  38. Taylor JF, Smith PG, Bull D, Pike MC: Kaposi’s sarcoma in Uganda: geographic and ethnic distribution. Br J Cancer 1972; 26:483-497.

  39. West RJ, Graham-Pole J, Hardisty RM, Pike MC: Factors in the pathogenesis of central-nervous system leukemia. Br Med J 1972; iii:311-314.

  40. Medical Research Council (Pike MC, member of Working Group): Report on the first myelomatosis trial. Br J Haem 1973; 24:123-139.

  41. Till MM, Hardisty RM, Pike MC: Long survivals in acute leukemia. Lancet 1973; i:534-538.

  42. Campbell AC, Hersey P, MacLennan ICM, Kay HEM, Pike MC: Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukemia. Br Med J 1973; ii:385-388.

  43. Medical Research Council (Pike MC, member of Working Group): Treatment of acute lymphoblastic leukemia: effect of “prophylactic” therapy against central nervous system leukemia. Br Med J 1973; ii:381-384.

  44. Brubaker G, Geser A, Pike MC: Burkitt’s lymphoma in the North Mara District of Tanzania 1964-1970: failure to find evidence of time-space clustering in a high risk isolated rural area. Br J Cancer 1973; 28:469- 472.

  45. Peto R, Pike MC: Conservatism of the approximation 2 (0-E)2/E in the logrank test for survival data or tumour incidence data. Biometrics 1973; 29:579-584.

  46. Revill WDL, Pike MC, Morrow RH, Ateng J: A controlled trial of the treatment of myocabacterium-ulcerans infection with clofazimine with some observations on the untreated clinical course of the disease. Lancet 1973; ii:873-877.

  47. Powles RL, Crowther D, Bateman CJT, Beard MEJ, McElwain TJ, Russell J, Lister TA, Whitehouse JMA, Wrigley PFM, Pike MC, Alexander P, Hamilton-Fairley G: Immunotherapy for acute myelogenous leukemia. Br J Cancer 1973; 28:365-376.

  48. Taylor JF, Shaw B, Bluming A, Briers P, Friedman E, Henderson BE, Horn C, Mohan S, Pike MC: Tropical myositis: clinical and laboratory studies. Afr J Med Sci 1973; iv:409-418.

  49. Smith PG, Pike MC: A note on a ’close pairs’ test for space clustering. Br J Prev Soc Med 1974; 28:63-64.

  50. Smith PG, Pike MC: Case clustering in Hodgkin’s disease: a brief review of the present position and report of current work in Oxford. Cancer Res 1974; 34:1156-1160.

  51. Pike MC, Smith PG: A case-control approach to examine diseases with long latent periods for evidence of contagion. Biometrics 1974; 30:263-279.

  52. Gerkins VR, Ting A, Menck HR, Casagrande JT, Terasaki PI, Pike MC, Henderson BE: HL-A heterozygosity as a genetic marker of long-term survival. J Natl Cancer Inst 1974; 52:1909-1911.

  53. Henderson BE, Powell D, Rosario I, Keys C, Hanisch R, Young M, Casagrande J, Gerkins V, Pike MC: An epidemiologic study of breast cancer. J Natl Cancer Inst 1974; 53:609-614.

  54. Gardner MB, Brown JC, Pike MC, Henderson BE: Feline leukemia virus: another viewpoint. Feline Practice 1974; 4:13-17.

  55. Pike MC, Smith PG: Clustering of cases of Hodgkin’s disease and leukemia. Cancer 1974; 34:1390-1394.

  56. Medical Research Council (Pike MC, member of Working Group): Treatment of acute myeloid leukemia. Br J Haem 1974; 27:373-389.

  57. Leighton P, Smith PG, Draper GJ, Pike MC: Malignant disease in the parents of children dying of Hodgkin’s disease. Br J Cancer 1974; 30:373- 375.

  58. Smith PG, Pike MC, Kinlen LJ, Jones A: Recent studies of person-person transmission of Hodgkin’s disease. Proc Roy Soc Med 1974; 67:683-684.

  59. Pike MC, Casagrande J, Smith PG: Statistical analysis of individually matched case-control studies in epidemiology: factor under study a discrete variable taking multiple values. Br J Prev Soc Med 1975; 29:196- 201.

  60. Ortega JA, Rivard GE, Isaacs H, Hittle RE, Hays DM, Pike MC, Karon MR: The influence of chemotherapy on the prognosis of rhabdomyosarcoma. J Med Pediac Onc 1975; 1:227-234.

  61. Menck HR, Henderson BE, Pike MC, Martin SP, Mack TM, SooHoo J: Cancer incidence in the Mexican American. J Natl Cancer Inst 1975; 55:531-536.

  62. Henderson BE, Gordon RJ, Menck HR, SooHoo J, Martin S, Pike MC: Lung cancer and air pollution in South-Central Los Angeles County. Am J Epidem 1975; 101:477-488.

  63. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC: Reserpine and breast cancer in a retirement community. New Engl J Med 1975; 292:1366-1371.

  64. Henderson BE, Gerkins V, Rosario I, Casagrande J, Pike MC: Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. New Engl J Med 1975; 293:790-795.

  65. Casagrande J, Pike MC: Reduced incidence of spontaneous tumors: another statistical analysis. Science 1975; 190:808-809.

  66. Gardner MB, Henderson BE, Estes JD, Rongey RW, Casagrande J, Pike MC, Huebner RJ: The epidemiology and virology of C-type virus-associated hematological cancers and related diseases in wild mice. Cancer Res 1976; 36:574-581.

  67. Morrow RH, Kisuule A, Pike MC, Smith PG: Burkitt’s lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria. J Natl Cancer Inst 1976; 56:479-484.

  68. Smith PG, Pike MC: Current epidemiological evidence for transmission of Hodgkin’s disease. Cancer Res 1976; 36:660-662.

  69. Roy S, Mishell DR, Pike MC, Azen SP, Casagrande J: Experience with the copper T and silicone shell loop intra-uterine contraceptive devices in parous women: a randomized study. Contraception 1976; 13:365-363.

  70. Smith PG, Pike MC, Till MM, Hardisty RM: Epidemiology of childhood leukemia in Greater London: a search for evidence of transmission assuming a possibly long latent period. Br J Cancer 1976; 33:1-8.

  71. Casagrande J, Gerkins VR, Henderson BE, Mack TM, Pike MC: Exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst 1976; 56:839-841.

  72. Azen SP, Roy S, Pike MC, Casagrande J: Some suggested improvements to current statistical methods of analyzing contraceptive efficacy. J Chron Dis 1976; 29:649-666.

  73. Smith PG, Pike MC: Generalizations of two tests for the detection of household aggregation of disease. Biometrics 1976; 32:817-828.

  74. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE: Estrogens and endometrial cancer in a retirement community. New Engl J Med 1976; 294:1262-1267.

  75. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976 34:585-612, and 1977; 35:1-39.

  76. Morrow RH, Pike MC, Smith PG: Further studies of spacetime clustering of Burkitt’s lymphoma in Uganda. Br J Cancer 1977; 35:668-673.

  77. Pike MC, Casagrande JT, Brown JB, Gerkins V, Henderson BE: Comparison of urinary and plasma hormone levels in daughters of breast cancer cases and controls. J Natl Cancer Inst 1977; 59:1351-1355.

  78. Wilkinson E, Clopton C, Gordonson J, Green R, Hill A, Pike MC: Mammographic parenchymal pattern and the risk of breast cancer. J Natl Cancer Inst 1977; 59:1397-1400.

  79. Smith PG, Pike MC, Kinlen LJ, Jones A, Harris R: A case-control study of contacts between young patients with Hodgkin’s disease. Lancet 1977; ii:59-62.

  80. Azen SP, Roy S, Pike MC, Casagrande J, Mishell DR: A new procedure for the statistical evaluation of intrauterine contraception. Am J Obstet Gynecol 1977; 128:329-335.

  81. Menck HR, Pike MC, Henderson BE, Jing JS: Lung cancer risk among beauticians and other female workers. J Natl Cancer Inst 1977; 59:1423- 1425.

  82. Hill AP, Pike MC, Smith PG, Ory HW: Stratified analysis of case-control studies with the factor under study taking multiple values. J Chron Dis 1978; 31:547-555.

  83. Katz D, Baptista J, Azen SP, Pike MC: Obtaining confidence intervals for the relative risk in cohort studies. Biometrics 1978; 34:469-474.

  84. Casagrande JT, Pike MC, Smith PG: An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978; 34:483-486.

  85. Casagrande JT, Pike MC, Smith PG: The power function of the “exact” test for comparing two binomial distributions. Appl Statist 1978; 27:176-180.

  86. Smith PG, Pike MC, Taylor E, Taylor JF: The epidemiology of tropical myositis in the Mengo Districts of Uganda. Trans Roy Soc Trop Med Hyg 1978; 72:46-53.

  87. Casagrande JT, Pike MC, Ross RK, Louie EW, Roy S, Henderson BE: “Incessant ovulation” and ovarian cancer. Lancet 1979; ii:170-173.

  88. Pike MC, Anderson J, Day NE: Some insights into Miettinen’s multivariate confounder score approach to case-control study analysis. Epidem Comm Health 1979; 33:104-106.

  89. Gray GE, Pike MC, Henderson BE: Breast cancer incidence and mortality rates in different countries in relation to known risk factors and dietary practices. Br J Cancer 1979; 39:1-7.

  90. Henderson BE, Benton B, Jing J, Yu MC, Pike MC: Risk factors for cancer of the testis in young men. Int J Cancer 1979; 23:598-602.

  91. Henderson BE, Dworsky R, Pike MC, Baptista J, Menck H, Preston-Martin S, Mack T: Risk factors for nodular sclerosis and other types of Hodgkin’s disease. Cancer Res 1979; 39:4507-4511.

  92. Medical Research Council (Pike MC, member of Working Group): Randomized trial of two-drug and four-drug maintenance chemotherapy in advanced or recurrent Hodgkin’s disease. Br Med J 1979; i:1105-1108.

  93. Pike MC, Casagrande JT: Cost considerations and sample size requirements in cohort and case-control studies. Am J Epidem 1979; 110:100-102.

  94. Preston-Martin S, Hill AP, Henderson BE, Pike MC, Wood C: Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst 1980; 65:67-73.

  95. Pike MC, Hill AP, Smith PG: Bias and efficiency in logistic analyses of stratified case-control studies. Int J Epidem 1980; 9:89-95.

  96. Gray GE, Henderson BE, Pike MC: Changing ratio of breast cancer incidence rates with age of Black females compared with White females in the United States. J Natl Cancer Inst 1980; 64:461-463.

  97. Bernstein L, Anderson J, Pike MC: Estimating the proportional hazard in two treatment group clinical trials. Biometrics 1981; 37:513-519.

  98. Pike MC, Henderson BE, Casagrande JT, Rosario I, Gray GE: Oral contraceptive use and early abortion as risk factors for breast cancer in young women. Br J Cancer 1981; 43:72-76.

  99. Roy S, Krauss RM, Mishell DR, Casagrande JT, Pike MC: The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol. Contraception 1981; 24:429-449.

  100. Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC: Elevated levels of prolactin in nulliparous women. Br J Cancer 1981; 43:826-831.

  101. Anderson J, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 1982; 38:407-416.

  102. Gray GE, Pike MC, Hirayama T, Tellez J, Gerkins V, Brown J, Casagrande JT, Henderson BE: Diet and hormone profiles in teenage girls in four countries at different risk to breast cancer. Prev Med 1982; 11:108-113.

  103. Gray GE, Williams P, Gerkins V, Brown J, Armstrong B, Phillips R, Casagrande JT, Pike MC, Henderson BE: Diet and hormone levels in Seventh-Day Adventist teenage girls. Prev Med 1982; 11:103-107.

  104. Preston-Martin S, Henderson BE, Pike MC: Descriptive epidemiology of cancers of the upper respiratory tract in Los Angeles County. Cancer 1982; 49:247-253.

  105. Henderson BE, Ross RK, Pike MC, Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42:3232-3239.

  106. Casagrande JT, Pike MC, Henderson BE: Menarcheal age and spontaneous abortion: a causal connection? Am J Epidemiol 1982; 115:481-483.

  107. Bernstein L, Kaldor J, McCann J, Pike MC: An empirical approach to the statistical analysis of mutagenesis data from the Salmonella test. Mutation Res 1982; 97:267-281.

  108. Pituitary Adenoma Study Group (Pike MC, member): Variation in assessing sella turcica tomograms for pituitary microadenomas. Obstet Gynecol 1982; 60:700-704.

  109. Depue RH, Pike MC, Henderson BE: Estrogen exposure during gestation and risk of testicular cancer. J Natl Cancer Inst 1983; 71:1151-1155.

  110. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A: The epidemiology of endometrial cancer in young women. Br J Cancer 1983; 47:749-756.

  111. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC: Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983; 48:437-440.

  112. Hoel DG, Wakabayashi T, Pike MC: Secular trends in the distributions of the breast cancer risk factors: menarche, first birth, menopause and weight, in Hiroshima and Nagasaki, Japan. Am J Epidemiol 1983; 118:78-89.

  113. Krailo MD, Pike MC: The estimation of the distribution of age at natural menopause from quantal data. Am J Epidemiol 1983; 117:356-361.

  114. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: ’Hormonal’ risk factors, ’breast tissue age’ and the age-incidence of breast cancer. Nature 1983; 303:767-770.

  115. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S: Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983; ii:926-930.

  116. Peters RK, Cady LD, Bischoff DP, Bernstein L, Pike MC: Physical fitness and subsequent myocardial infarction in healthy workers. J Am Med Assoc 1983; 249:3052-3056.

  117. Ottman R, Pike MC, King MC, Henderson BE: Practical guide for estimating risk for familial breast cancer. Lancet 1983; ii:556-558.

  118. Yu MC, Mack T, Hanisch R, Peters RL, Henderson BE, Pike MC: Hepatitis, alcohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. Cancer Res 1983; 43:6077-6079.

  119. Pituitary Adenoma Study Group (Pike MC, member): Pituitary adenomas and oral contraceptives: a multicenter case-control study. Fertil Steril 1983; 39:753-760.

  120. Gold LA, Sawyer CB, Magaw R, Backman GM, de Veciana M, Levinson R, Hooper NK, Havender WR, Bernstein L, Peto R, Pike MC, Ames BA. A carcinogenic potency database of the standardized results of animal bioassays. Environ Health Perspect 1984; 58:9-319.

  121. Peto R, Pike MC, Bernstein L, Gold LS, Ames BN: The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ Health Perspect 1984; 58:1-8.

  122. Sawyer C, Peto R, Bernstein L, Pike MC: Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 1984; 40:27-40.

  123. Paganini-Hill A, Krailo MD, Pike MC: Age at natural menopause and breast cancer risk: the effect of errors in recall. Am J Epidem 1984; 119:81-85.

  124. Chilvers C, Pike MC, Forman D, Fogelman K, Wadsworth MEJ. Apparent doubling of frequency of undescended testis in England and Wales in 1962-81. Lancet 1984; ii:330-332.

  125. Ross RK, Paganini-Hill A, Krailo MD, Gerkins VR, Henderson BE, Pike MC. Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women. Cancer Res 1984; 44:3106-3108.

  126. Walker AH, Ross RK, Pike MC, Henderson BE. A possible rising incidence of malignant germ cell tumors in young women. Br J Cancer 1984; 49:669-672.

  127. Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone binding globulin levels in nulliparous and parous women. J Natl Cancer Inst 1985; 74:741-745.

  128. Pike MC, Bernstein L. Statistical errors invalidate conclusions in “Caffeine and unsaturated fat diet significantly promotes DMBA-induced breast cancer in rats”. Cancer 1985; 55:1855-1857.

  129. Bernstein L, Gold LS, Ames BN, Pike MC, Hoel DG: Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fund Appl Toxicol 1985; 5:79-86.

  130. Wu AH, Henderson BE, Pike MC, Yu MC: Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst 1985; 74:747-751.

  131. Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC: Do regular ovulatory cycles increase breast cancer risk? Cancer 1985; 56:1206-1208.

  132. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986; 76:45-48.

  133. Ottman R, Pike MC, King M-C, Casagrande JT, Henderson BE: Familial breast cancer in a population based series. Am J Epidem 1986; 123:15-21.

  134. Chilvers C, Dudley NE, Gough MH, Jackson MB, Pike MC: Undescended testis: the effect of treatment on subsequent risk of sub-fertility and malignancy. J Ped Surg 1986; 21:691-696.

  135. John Radcliffe Hospital Cryptorchidism Study Group (Pike MC, Principal Investigator): Boys with late descending testes - the source of “retractile” testes undergoing orchidopexy? Br Med J 1986; 293:789-790.

  136. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT: Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J 1986; 293:359-362.

  137. Pike MC, Chilvers C, Peckham MJ: Effect of age at orchidopexy on risk of testicular cancer. Lancet 1986; i:1246-1248.

  138. Bernstein L, Chilvers C, Murrells T, Pike MC: Month of birth of men with malignant germ cell tumors of the testis. J Epidem Comm Hlth 1986; 40:214-217.

  139. Deapen DM, Pike MC, Casagrande JT, Brody GS: The relationship between breast cancer and augmentation mammaplasty: an epidemiologic study. Plastic Reconst Surg 1986; 77:361-367.

  140. John Radcliffe Hospital Cryptorchidism Study Group (Pike MC, Principal Investigator): Cryptorchidism: an apparent substantial increase since 1960. Br Med J 1986; 293:1401-1404.

  141. Bernstein L, Depue RH, Ross RK, Judd HL, Pike MC, Henderson BE: Higher maternal levels of free estradiol in first compared to second pregnancy: early gestational differences. J Natl Cancer Inst 1986; 76:1035-1039.

  142. Chilvers C, Pike MC, Peckham MJ: Torsion of the testis: a new risk factor for testicular cancer. Br J Cancer 1986; 55:105-106.

  143. Preston-Martin S, Bernstein L, Pike MC, Maldonado AA, Henderson BE: Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br J Cancer 1986; 55:191-195.

  144. Forman D, Cook-Mozaffari P, Darby S, Davey G, Stratton I, Doll R, Pike MC: Cancer near nuclear installations. Nature 1987; 329:499-505.

  145. Pike MC, Chilvers CED, Bobrow LG: Classification of testicular cancer in incidence and mortality statistics. Br J Cancer 1987; 56:83-85.

  146. Pike MC: Age-related factors in cancers of the breast, ovary, and endometrium. J Chron Dis 1987; 40 (Suppl 2):59S-69S.

  147. Key TJA, Darby SC, Pike MC: Trends in breast cancer mortality and diet in England and Wales from 1911 to 1980. Nutr Cancer 1987; 10:1-9.

  148. Krailo M, Thomas DC, Pike MC: Fitting models of carcinogenesis to a case-control study of breast cancer. J Chron Dis 1987; 40 (Suppl 2):181S-189S.

  149. Chilvers C, Mant D, Pike MC: Cervical adenocarcinoma and oral contraceptives. Br Med J 1987; 295:1446-1447.

  150. Moore JW, Key TJA, Bulbrook RD, Clark GMG, Allen DS, Wang DY, Pike MC: Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones. Br J Cancer 1987; 56:661-666.

  151. Bernstein L, Pike MC, Depue RH, Ross RK, Moore JW, Henderson BE: Maternal hormone levels in early gestation of cryptorchid males: a case-control study. Br J Cancer 1988; 58:379-381.

  152. Casagrande JT, Hanisch R, Pike MC, Ross RK, Brown JB, Henderson BE: A case-control study of male breast cancer. Cancer Res 1988; 48:1326-1330.

  153. Key TJA, Pike MC: The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24:29-43.

  154. Key TJA, Pike MC: The dose-effect relationship between ’unopposed’ oestrogens and endometrial mitotic rate: Its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988; 57:205-212.

  155. Henderson BE, Pike MC, Ross RK, Mack TM, Lobo RA: Re-evaluating the role of progestogen therapy after the menopause. Fertil Steril 1988; 49 (Suppl): 9-15.

  156. Darby SC, Pike MC: Lung cancer and passive smoking: predicted effects from a mathematical model for cigarette smoking and lung cancer. Br J Cancer 1988; 58:825-831.

  157. John Radcliffe Hospital Cryptorchidism Study Group (Pike MC, Principal Investigator): Clinical diagnosis of cryptorchidism at birth. Arch Dis Childh 1988; 63:587-591.

  158. Grocock CA, Charlton HM, Pike MC: Role of the fetal pituitary in cryptorchidism induced by exogenous maternal oestrogen during pregnancy in mice. J Reprod Fert 1988; 83:295-300.

  159. Westhoff C, Pike MC, Vessey M: Benign ovarian teratomas: a population-based case-control study. Br J Cancer 1988; 58:93-98.

  160. Bernstein L, Pike MC, Lobo RA, Depue RH, Ross RK, Henderson BE: Cigarette smoking in pregnancy results in marked decrease in maternal hCG and oestradiol levels. Br J Obstet Gynecol 1989; 96:92-96.

  161. Pike MC, Ross RK, Lobo RA, Key TJA, Potts M, Henderson BE: LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 1989; 60:142-148.

  162. Pike MC, Bernstein L, Peters RK: Re: “Total energy intake: implications for epidemiologic analyses”. Am J Epidemiol 1989; 129:1312-1313.

  163. Pike MC, Robins J: Re: “Possibility of selection bias in matched case-control studies using friend controls”. Am J Epidemiol 1989; 130:209-210.

  164. Key TJA, Pike MC, Moore JW, Bulbrook RD, Clark GMG, Allen DS, Wang DY: The relationships of SHBG with current and previous use of oral contraceptives and oestrogen replacement therapy. Contraception 1989; 39:179-186.

  165. UK National Breast Cancer Case-Control Study Group (Pike MC, Principal Investigator): Oral contraceptive use and breast cancer risk in young women. Lancet 1989; ii:973-982.

  166. Key TJA, Chen J, Wang DY, Pike MC, Boreham J: Sex hormones in women in rural China and in Britain. Br J Cancer 1990; 62:631-636.

  167. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE: Hormone levels in older women: A study of postmenopausal breast cancer patients and healthy population controls. Br J Cancer 1990; 61:298-302.

  168. Bernstein L, Yuan J-M, Ross RK, Pike MC, Lobo RA, Stanczyk F, Gao Y-T, Henderson BE: Serum hormone levels in premenopausal Chinese women in Shanghai and White women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1990; 1:51-58.

  169. Key TJA, Pike MC, Moore JW, Wang DY, Morgan B: The relationship of free fatty acids with the binding of oestradiol to SHBG and to albumin in women. J Steroid Biochem 1990; 35:35-38.

  170. Key TJA, Pike MC, Wang DY, Moore JW: Long term effects of a first pregnancy on serum concentrations of dehydroepiandrosterone sulphate and dehydroepiandrosterone. J Clin Endocrinol Metab 1990; 70:1651-1653.

  171. Peters RK, Pike MC, Chang WWL, Mack TM: Reproductive factors and colon cancer. Br J Cancer 1990; 61:741-748.

  172. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 1990; 50:7415-7421.

  173. Robins J, Pike MC: The validity of case-control studies with nonrandom selection of controls. Epidemiol 1990; 1:273-284.

  174. Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE: Serum estrogen levels in postmenopausal women: comparison of US whites and Japanese in Japan. Br J Cancer 1990; 62:451-454.

  175. UK National Breast Cancer Case-Control Study Group (Pike MC, Principal Investigator): Oral contraceptive use and breast cancer risk in young women: subgroup analyses. Lancet 1990; 335:1507-1509.

  176. Finch CE, Pike MC, Witten M: Slow mortality rate accelerations during aging in some animals approximate that of humans. Science 1990; 249:902-905.

  177. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC: From gene to carcinogen: A rapidly evolving field in molecular epidemiology. Cancer Res 1991; 51:3617-3620.

  178. Henderson BE, Ross RK, Pike MC: Toward the primary prevention of cancer. Science 1991; 254:1131-1138.

  179. Key TJA, Pike MC, Baron JA, Moore JW, Wang DY, Thomas BS, Bulbrook RD: Cigarette smoking and steroid hormones in women. J Steroid Biochem Molec Biol 1991; 39:529-534.

  180. Spicer DV, Shoupe D, Pike MC: GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception 1991; 44:289-310.

  181. Bernstein L, Pike MC, Ross RK, Henderson BE: Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 1991; 2:221-225.

  182. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, Willson E, Brynes R, Parker J, Rasheed S, Gill PS: Human immunodeficiency virus-related lymphoma. Cancer 1991; 68:2466-2472.

  183. Aledort LM, Hilgartner MW, Pike MC, Gjerset GF, Koerper MA, Lian EYC, Lusher JM, Mosley JW, and the Transfusion Safety Study Group: Variability in serial CD4 counts and relation to progression HIV-I infection to AIDS in haemophilic patients. Br Med J 1992; 304:212-216.

  184. Coleman MP, Key TJA, Wang DY, Hermon C, Fentiman IS, Allen DS, Jarvis M, Pike MC, Sanders TAB: A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992; 92:177-185.

  185. Spicer DV, Pike MC: The prevention of breast cancer through reduced ovarian steroid exposure. Acta Oncol 1992; 31:167-174.

  186. Forman D, Oliver RTD, Brett AR, Marsh SGE, Moses JH, Bodmer JG, Chilvers CED, Pike MC: Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA Class 1 sib-pair analysis. Br J Cancer 1992; 65:255-262.

  187. Peters RK, Pike MC, Garabrant D, Mack TM. Diet and colon cancer in Los Angeles County. Cancer Causes Control 1992; 3:457-473.

  188. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339:887-889.

  189. Cassidenti DL, Pike MC, Vigod AG, Stanczyk, FZ, Lobo, RA: A reevaluation of estrogen status in postmenopausal women who smoke. Am J Obstet Gynecol 1992; 166: 1444-1448.

  190. John Radcliffe Hospital Cryptorchidism Study Group ( Pike MC, Principal Investigator): Cryptorchidism: a prospective study of 7500 consecutive male births, 1984-8. Arch Dis Child 1992; 67:892-899.

  191. Baert L, Ameye F, Pike MC, Willemen P, Astrahan MA, Petrovich Z: Transurethral hyperthermia for benign prostatic hyperplasia patients with retention. J Urol 1992; 147:1558-1561.

  192. Pike MC, Bernstein L, Peters RK: Re: “Dietary fat and postmenopausal breast cancer”. J Natl Cancer Inst 1992; 84:1666-1667.

  193. Petrovich Z, Ameye F, Pike MC, Boyd S, Baert L. Relationship of response to transurethral hyperthermia and prostate volume in BPH patients. Urology 1992; 40:317-321.

  194. Hilgartner MW, Buckley JD, Operskalski EA, Pike MC, Mosley JW: Purity of factor VIII concentrates and serial CD4 counts. Lancet 1993; 341:1373-1374.

  195. Jha PKS, Beral V, Peto J, Hack S, Hermon C, Deacon J, Mant D, Chilvers C, Vessey MP, Pike MC, Muller M, Gissmann L: Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993; 341:1116-1118.

  196. Ponnighaus JM, Fine PEM, Bliss L, Gruer PJK, Kapira-Mwamondwe B, Msosa E, Rees RJW, Clayton D, Pike MC, Sterne JAC, Oxborrow SM: The Karonga prevention trial: a leprosy and tuberculosis vaccine trial in Northern Malawi. I. Methods of the vaccination phase. Lepr Rev 1993; 64:338-356.

  197. Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J: Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 1993; 47:427-444.

  198. Henderson BE, Ross RK, Pike MC: Hormonal chemoprevention of cancer in women. Science 1993; 259:633-638.

  199. Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15:17-35.

  200. Spicer DV, Pike MC: Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat 1993; 28:179-193.

  201. Press MF, Pike MC, Chazin, VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-4970.

  202. Preston-Martin S, Pike MC, Ross RK, Henderson BE: Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 1993; 5:137-138.

  203. UK National Breast Cancer Case-Control Study Group (Pike MC, Principal Investigator): Breast feeding and risk of breast cancer in young women. Br Med J 1993; 307:17-20.

  204. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AMY, West DW, Wu-Williams AH, Kolonel LN, Horn-Ross PL, Rosenthal JF, Hyer MB: Migration patterns and breast cancer risk. J Natl Cancer Inst 1993; 85:1819-1827.

  205. Chilvers CED, Pike MC, Taylor CN, Hermon C, Crossley B, Smith SJ, UK National Case-Control Study Group: General practitioner notes as a source of information for case-control studies in young women. J Epidemiol Community Health 1994; 48:92-97.

  206. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 1994; 86:431-436.

  207. Smith SJ, Deacon JM, Chilvers CED, members of the UK National Breast Cancer Case-Control Study Group (Pike MC, Principal Investigator): Alcohol, smoking, passive smoking and caffeine in relation to breast cancer risk in young women. Br J Cancer 1994; 70:112-119.

  208. Parkinson MC, Swerdlow AJ, Pike MC: Carcinoma in situ in boys with cryptorchidism: when can it be detected? Br J Urol 1994; 73:431-435.

  209. UK Testicular Cancer Study Group (Pike MC, member): Social, behavioural and medical factors in the aetiology of testicular cancer: results from the UK study. Br J Cancer 1994; 70:513-520.

  210. UK Testicular Cancer Study Group (Pike MC, member): The aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility and exercise. Br Med J 1994; 308:1393-1399.

  211. Eaton SB, Pike MC, Short RV, Lee NC, Trussell J, Hatcher RA, Wood JW, Worthman CM, Blurton Jones NG, Konner MJ, Hill KR, Bailey R, Hurtado AM: Women’s reproductive cancers in evolutionary context. Q Rev Biol 1994; 69:353-367.

  212. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, El-Naggar AK: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54:5675-5682.

  213. Ursin G, Peters RK, Henderson BE, d’Ablaing III G, Monroe KR, Pike MC: Oral contraceptive use and adenocarcinoma of the cervix. Lancet 1994; 344:1390-1394.

  214. Baert L, Ameye F, Pike MC, Petrovich Z: Optimization of transurethral hyperthermia: number of treatments. Urology 1994; 43:567-571.

  215. Gjerset GF, Pike MC, Mosley JW, Hassett J, Fletcher MA, Donegan E, Parker JW, Counts RB, Zhou Y, Kasper CK, Operskalski EA, Transfusion Safety Study Group: Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Blood 1994; 84:1666-1671.

  216. Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, Tokunaga M: A case-control interview study of breast cancer among Japanese A-bomb survivors. I. Main effects. Cancer Causes & Control 1994; 5:157-165.

  217. Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, Tokunaga M: A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes & Control 1994; 5:167-176.

  218. Bartow SA, Pathak DR, Mettler FA, Key CR, Pike MC: Breast mammographic pattern: a concatenation of confounding and breast cancer risk factors. Am J Epidemiol 1995; 142:813-819.

  219. Reichardt JKV, Makridakis N, Henderson B, Yu MC, Pike MC, Ross RK: Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk. Cancer Res 1995; 55:3973-3975.

  220. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, Kornblau S, Pike MC, Levine AM: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332:1744-1748.

  221. Collaborative Group on Hormonal Factors in Breast Cancer (Pike MC, member). Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347:1713-1727.

  222. Spicer DV, Krecker EA, Pike MC: The endocrine prevention of breast cancer. Cancer Invest 1995; 13:495-504.

  223. Stram DO, Longnecker MP, Shames L, Kolonel LN, Wilkens LR, Pike MC, Henderson BE: Cost-efficient design of a diet validation study. Am J Epidemiol 1995; 142:353-362.

  224. Pike MC, Ursin G, Spicer DV: Experiments on proliferation of normal human breast tissue in nude mice do not show that progesterone does not stimulate breast cells. Endocrinology 1996; 137:1505-1506.

  225. Key TJA, Bull D, Ansell P, Brett AR, Clark GMG, Moore JW, Chilvers CED, Pike MC: A case-control study of cryptorchidism and maternal hormone concentrations in early pregnancy. Br J Cancer 1996; 73:698-701.

  226. Wu AH, Ziegler RG, Pike MC, Nomura AMY, West DW, Kolonel LN, Horn-Ross PL, Rosenthal JF, Hoover RN: Menstrual and reproductive factors and risk of breast cancer in Asian Americans. Br J Cancer 1996; 73:680-686.

  227. Finch CE, Pike MC: Maximum life span predictions from the Gompertz mortality model. J Gerontology 1996; 51A:B183-B194.

  228. Petrovich Z, Pike MC, Astrahan MA, Luxton G, Murphree AL, Liggett PE: Episcleral plaque thermoradiotherapy of posterior uveal melanomas. Am J Clin Oncol 1996; 19:207-211.

  229. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-Related Kaposis’ Sarcoma. J Clin Oncol 1996; 14:2353-2364.

  230. Key TJA, Wang DY, Brown JB, Hermon C, Allen DS, Moore JW, Bulbrook RD, Fentiman IS, Pike MC: A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer 1996; 73:1615-1619.

  231. Ziegler RG, Hoover RN, Nomura AMY, West DW, Wu AH, Pike MC, Lake AJ, Horn-Ross PL, Kolonel LN, Siiteri PK, Fraumeni Jr. JF: Relative weight, weight change, height, and breast cancer risk in Asian-American women. J Natl Cancer Inst 1996; 88:650-660.

  232. Wu AH, Ziegler RG, Horn-Ross PL, Nomura AMY, West DW, Kolonel LN, Rosenthal JF, Hoover RN, Pike MC. Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol, Biomark Prev 1996; 5:901-906.

  233. Karonga Prevention Trial Group (Pike MC, member). Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed myobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348:17-24.

  234. Collaborative Group on Hormonal Factors in Breast Cancer (Pike MC, member). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350:1047-1059.

  235. Devgan SA, Henderson BE, Yu MC, Shi, C-Y, Pike MC, Ross RK, Reichardt JKV. Genetic variation of 3-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997; 33:9-12.

  236. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi C-Y, Yu MC, Henderson BE, Reichardt JKV. A prevalent missense substitution that modulates activity of prostatic steroid 5-reductase. Cancer Res 1997; 57:1020-1022.

  237. Pike MC, Daniels JR, Spicer DV. A hormonal contraceptive approach to reducing breast and ovarian cancer risk: an update. Endocrine-Related Cancer 1997; 4:125-133.

  238. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89:1110-1116.

  239. Swerdlow AJ, Higgins CD, Pike MC: Risk of testicular cancer in a cohort of boys with cryptorchidism. Br Med J 1997;314:1507-1511.

  240. Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep Anh, Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997; 57:3678-3681.

  241. Nathwani BN, Clarke K, Lincoln T, Berard C, Taylor C, Patil R, Pike MC, Azen S. Evaluation of an expert system on lymph node pathology. Hum Pathol 1997; 28:1097-1110.

  242. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike M. A pilot study of urinary estrogen metabolites (16a-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect 1997; 105 (Suppl 3):601-605.

  243. Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, Pike MC, Ross RK. The effect of finasteride on the prostate gland in men with elevated serum prostate specific antigen (PSA) levels. Br J Cancer 1998; 78:413-418.

  244. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17 gene CYP17 polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58:585-587.

  245. Pike MC, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998; 147:718-721.

  246. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigleson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998; 58:4497-4504.

  247. Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV. The detection of changes in mammographic densities. Cancer Epidemiol Biomark Prevention 1998; 7:43-47.

  248. Wu AH, Ziegler RG, Nomura AM, West DW, Kolonel LN, Horn-Ross PL, Hoover RN, Pike MC. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr 1998; 68 (Suppl 6):1437S-1443S.

  249. Coupland CA, Chilvers CE, Davey G, Pike MC, Oliver RT, Forman D. Risk factors for testicular germ cell tumours by histological tumour type. United Kingdom Testicular Cancer Study Group. Br J Cancer 1999; 80:1859-1863.

  250. Feigelson HS, McKean-Cowdin R, Pike MC, Coetzee GA, Kolonel LN, Nomura AMY, Le Marchand LL, Henderson BE. Cytochrome P450c17 gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res 1999; 59:3908-3910.

  251. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JKV. Association of mis-sense substitution in the SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999; 354: 975-978.

  252. Ursin G, London S, Stanczyk F, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC. Urinary 2-hydroxyestrone/16-hydroxyestrone ratio and the risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91:1067-1072.

  253. Wu AH, Pike MC, Stram DO. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999; 91:529-534.

  254. Zheng W, Lu JJ, Luo F, Zheng Y, Feng Y-J, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 1999; 76:80-88.

  255. Formenti S, Felix J, Salonga D, Danenberg K, Pike MC, Danenberg P. Expression of metastases-associated genes in cervical cancers resected in the proliferative and secretory phases of the menstrual cycle. Clin Cancer Res 2000; 6:4653-4657.

  256. Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocrine-Related Cancer 2000; 7:73-83.

  257. Probst-Hensch NM, Pike MC, McKean-Cowdin R, Stanczyk FZ, Kolonel LN, Henderson BE. Ethnic differences in postmenopausal plasma oestrogen levels: high oestrone levels in Japanese-American women despite low weight. Br J Cancer 2000; 82:1867-1870.

  258. Zheng W, Luo F, Lu JJ, Baltayan A, Press MF, Zhang Z-F, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol 2000; 76:294-300.

  259. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Estrogen versus estrogen-progestin hormone replacement therapy: effect on breast cancer risk. J Natl Cancer Inst 2000; 92:328-332.

  260. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000; 65:659-664.

  261. Stram DO, Hankin JH, Wilkens LR, Pike MC, Monroe KR, Park S, Henderson BE, Nomura AMY, Earle ME, Nagamine FS, Kolonel LN. Calibration of the dietary questionnaire for a Multiethnic Cohort in Hawaii and Los Angeles. Am J Epidemiol 2000; 151:358-370.

  262. Kolonel LN, Henderson BE, Hankin JH, Nomura AMY, Wilkens LR, Pike MC, Stram DO, Monroe KR, Earle ME, Nagamine FS. A multiethnic cohort in Hawaii and Los Angeles: Baseline characteristics. Am J Epidemiol 2000; 151:346-357.

  263. Lu JJ, Zheng Y, Kang X, Yuan JM, Lauchlan SC, Pike MC, Zheng W. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 2000; 79:158-168.

  264. McKean-Cowdin R, Feigelson HS, Ross RK, Pike MC, Henderson BE. Declining cancer rates in the 1990s. J Clin Oncol 2000; 18:2258-68.

  265. Spicer DV, Pike MC. Future possibilities in the prevention of breast cancer: luteinizing hormone-releasing hormone agonists. Breast Cancer Res 2000; 2:264-267.

  266. Wu AH, Stanczyk F, Hendrich S, Murphy PA, Zhang C, Wan P, Pike MC. Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 2000; 82:1879-1886.

  267. Wu AH, Yang D, Pike MC. A meta-analysis of soyfoods and risk of stomach cancer: The problem of potential confounders. Cancer Epidemiol Biomark Prev 2000; 9:1051-1058.

  268. Gram IT, Ursin G, Spicer DV, Pike MC. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment. Cancer Epidemiol Biomark Prev 2001; 10:1117-1120.

  269. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE. Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 2001; 61:8393-8394.

  270. McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 2001; 61:848-849.

  271. Ursin G, Parisky YR, Pike MC, Spicer DV. Mammographic density changes during the menstrual cycle. Cancer Epidemiol Biomark Prev 2001; 10:141-142.

  272. Haiman CA, Pike MC, Bernstein L, Jaque SV, Stancyzk FZ, Afghani A, Peters RK, Wan P, Shames L. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer 2002; 86:367-371.

  273. Ursin G, Tseng C-C, Paganini-Hill A, Enger S, Wan PC, Formenti S, Pike MC, Ross RK. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002; 20:699-706.

  274. Ursin G, London S, Yang D, Tseng CC, Pike MC, Bernstein L, Stanczyk FZ, Gentzschein E. Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 2002; 72:139-43.

  275. Zhou H, Luo MP, Schönthal AH, Pike MC, Stallcup MR, Blumenthal B, Zheng W, Dubeau L. Effect of reproductive hormones on ovarian epithelial tumors. I. Effect on cell cycle activity. Cancer Biol Ther 2002, 1:300-306.

  276. Pike MC, Kolonel LN, Henderson BE, Wilkens LR, Hankin JH, Feigelson HS, Wan P, Stram DO, Nomura AMY. Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factors-adjusted incidence in Japanese equals and in Hawaiians exceeds that in Whites. Cancer Epidemiol Biomark Prev 2002;11:795-800.

  277. Pearce CL, Makridakis N, Ross R, Pike MC, Kolonel L, Henderson BE, Reichardt J. Steroid 5--reductase type II V89L substitution is not associated with risk of prostate cancer in a multi-ethnic population study. Cancer Epidemiol Biomark Prev 2002; 11:417-418.

  278. Cozen W, Peters R, Reichardt JKV, Ng W, Felix JC, Wan P, Pike MC. Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption and the risk of borderline and invasive ovarian cancer (United States). Cancer Causes Control 2002; 13:113-120.

  279. Falk RT, Fears TR, Hoover RN, Pike MC, Wu AH, Nomura AM, Kolonel LN, West DW, Ziegler RG. Does place of birth influence endogenous hormone levels in Asian-American women? Br J Cancer 2002; 87:54-60.

  280. Wu AH, Wan P, Hankin J, Tseng C-C, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis 2002; 23:1491-1496.

  281. Collaborative Group on Hormonal Factors in Breast Cancer (Pike MC, member). Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 2002; 87:1234-1245.

  282. Pike MC, Ross RK. Estrogen-progestin replacement therapy: regulatory action needed. Breast Cancer Res 2002; 4:222-223.

  283. Collaborative Group on Hormonal Factors in Breast Cancer (Pike MC, member). Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002; 360:187-195.

  284. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95:30-37.

  285. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer 2003; 106:574-579.

  286. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPs based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.

  287. Monroe KR, Hankin JH, Pike MC, Henderson BE, Stram DO, Park S, Nomura AMY, Wilkens LR, Kolonel LN. Correlation of dietary intake and colorectal cancer incidence among Mexican-American migrants: The Multiethnic Cohort Study. Nutr Cancer 2003;45:133-147.

  288. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D, Hirschhorn J, Henderson BE. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort Study. Hum Molec Genet 2003; 12:2679-2692.

  289. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomark Prev 2003; 12:332-338.

  290. Green J, de Gonzalez AB, Sweetland S, Beral V, Chilvers C, Crossley B, Deacon J, Herman C, Jha P, Mant D, Peto J, Pike M, Vessey MP. Risk factors for adenocarcinoma and squamous cell carcinoma of the cervix in women aged 20-44 years: The UK National Case-Control Study of Cervical Cancer. Br J Cancer 2003; 89:2078-2086.

  291. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182.

  292. Ursin G, Palla SL, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Greendale GA. Post-treatment change in serum estrone predicts mammographic density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Clin Oncol 2004; 22:2842-2848.

  293. Coupland C, Forman D, Chilvers C, Davey G, Pike MC, Oliver T. Maternal risk factors for testicular cancer: a population-based case-control study (UK). Cancer Causes Control 2004; 15:277-283.

  294. Collaborative Group on Hormonal Factors in Breast Cancer (Pike MC, member). Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet 2004; 303:1007-1016.

  295. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 2004; 82:186-195.

  296. Pike MC, Pearce CL, Wu AH. Prevention of cancer of the breast, endometrium and ovary. Oncogene 2004; 23:6379-6391.

  297. Cozen W, Gill PS, Ingles SA, Masood R, Martinez-Maza O, Cockburn MG, Gauderman WJ, Pike MC, Bernstein L, Nathwani BN, Salam MT, Danley KL, Wang W, Gage J, Gundell-Miller S, Mack TM. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103:3216-3221.

  298. Chen Z, Wu AH, Gauderman WJ, Bernstein L, Ma H, Pike MC, Ursin G. Does mammographic density reflect ethnic differences in breast cancer incidence rates? Am J Epidemiol 2004; 159:140-147.

  299. Lord SJ, Mack WJ, van den Berg D, Pike MC, Ingles S, Haiman CA, Wang W, Parisky YR, Hodis HN, Ursin G. Polymorphisms in genes involved in steroid hormone metabolism and mammographic density changes in women randomized to menopausal estrogen and progesterone therapy. Cancer 2005; 101:353-362.

  300. Pearce CL, Hirschhorn JN, Wu AH, Burtt NP, Stram DO, Young S, Kolonel LN, Henderson BE, Altshuler D, Pike MC. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 2005; 97:51-59.

  301. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005; 92:2049-2058.

  302. Daneshmand S, Dorff TB, Quek ML, Cai J, Pike MC, Nichols PW, Pinski J. Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue. Urology 2005; 65:1008-1012.

  303. Ursin G, Howanessian-Larsen L, Parisky YR, Pike MC, Wu AH. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 2005; 7:R605-R608.

  304. Wu AH, Stanczyk FZ, Martinez C, Tseng C-C, Hendrich S, Murphy Patricia, Chaikittisilpa S, Stram DO, Pike MC. A controlled 2-mo dietary fat reduction and soy food supplementation study in postmenopausal women. Am J Clin Nutr 2005; 81:1133-1141.

  305. Falk RT, Fears TR, Xu X, Hoover RN, Pike MC, Wu AH, Nomura AMY, Kolonel LN, West DW, Sepkovic DW, Bradlow HL, Ziegler RG. Urinary estrogen metabolites and their ratio among Asian American women. Cancer Epidemiol Biomarkers Prev 2005; 14:221-226.

  306. Chodankar R, Kwang S, Sanglorg F, Hong H, Yen H-Y, Deng C, Pike MC, Shuler CF, Maxson R, Dubeau L. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional BRCA1 in ovarian granulosa cells. Current Biology 2005; 15:561-565.

  307. Cheng I, Yu MC, Koh W-P, Pike MC, Kolonel LN, Henderson BE, Stram DO. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States. Cancer Epidemiol Biomark Prev 2005; 14:1692-1696.

  308. Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Mammographic Density Study. Am J Epidemiol 2005; 162:826-834.

  309. Gago-Dominguez M, Castelao E, Pike MC, Sevanian A, Haile RW. Role of lipid peroxidation in the epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:2829-2839.

  310. Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani A. Is mammographic density, as currently measured, a robust surrogate marker for breast cancer? Gynecol Endocrinol 2005; 21:17-21.

  311. Pike MC. The role of mammographic density in evaluating changes in breast cancer risk. Gynecol Endocrinol 2005; 21:1-5.

  312. Magnusson CMK, Roddam AW, Pike MC, Chilvers C, Crossley B, Hermon C, McPherson K, Peto J, Vessey M, Beral V. Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women. Br J Cancer 2005; 93:817-824.

  313. Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burtt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Marchand LL, Ma J, Overvad K, Palli D, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S. Genetic variation in the HSD17B1 gene and risk of prostate cancer. Plos Genetics 2005; e68:603-613.

  314. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, Haynes RB, Henderson BE, Kaaks R, Stram DO, Thomas G, Thun MJ, Blanche H, Buring JE, Burtt NP, Calle EE, Cann H, Canzian F, Chen YC, Colditz GA, Cox DG, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hirschhorn JN, Hoover RN, Key T, Kolonel LN, Kraft P, Le Marchand L, Liu S, Ma J, Melnick S, Pharaoh P, Pike MC, Rodriguez C, Setiawan VW, Stampfer MJ, Trapido E, Travis R, Virtamo J, Wacholder S, Willett WC; National Cancer Institute Breast and Prostate Cancer Cohort Consortium. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005; 5:977-985.

  315. Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaiti-Pellie C, Heidenreich A, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Oosterhuis JW, Gillis AJ, Looijenga LH, Guilford P, Fossa SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Rudd M, Huddart R, Crockford GP, Forman D, Oliver DT, Einhorn L, Weber BL, Kramer J, McMaster M, Greene MH, Pike MC, Cortessis V, Chen C, Schwartz SM, Bishop DT, Easton DF, Stratton MR, Rapley EA. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet 2005; 77:1034-1043.

  316. Lord SJ, Mack WJ, Van Den Berg D, Pike MC, Ingles SA, Haiman CA, Wang W, Parisky YR, Hodis HN, Ursin G. Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Br Cancer Res 2005; 7:R336-R344.

  317. Cheng I, Stram DO, Penney KL, Pike MC, Le Marchand L, Kolonel LN, Hirschhorn J, Altshuler D, Henderson BE, Freedman ML. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst 2006; 98:123-134.

  318. Hawes D, Downey S, Pearce CL, Bartow S, Wan P, Pike MC, Wu AH. Dense breast stromal tissue shows greatly increased concentration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res 2006; 8:R24-R29.

  319. Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burtt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 2006; 66:2468-2475.

  320. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354:333-342.

  321. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort Study. Int J Cancer 2006; 118:1285-1291.

  322. Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL,Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA,Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A,Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomark Prev 2006; 15:1863-1870.

  323. Stram DO, Hankin JH, Wilkens LR, Park S, Henderson BE, Nomura AM, Pike MC, Kolonel LN. Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study (United States). Cancer Causes Control 2006; 17:1193-1207.

  324. Setiawan VW, Cheng I, Stram DO, Giorgi E, Pike MC, Van Den Berg D, Pooler L, Burtt NP, Le Marchand L, Altshuler D, Hirschhorn J, Henderson BE, Haiman CA. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer. Cancer Res 2006; 66:12019-12025.

  325. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006; 8: R43. 8:R43.

  326. Wu AH, Yu MC, Tseng C-C, Pike MC. Body size, hormone therapy and risk of breast cancer in Asian-American women. Int J Cancer 2007; 120: 844-852.

  327. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning A, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Cale EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes R, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel L, LeMarchand L, Lenner Per, Lund E, Panico R, Peeters P, Pike MC, Riboli E, Tjonneland A, Travis R, Trichopoulos D, Wacholder S, Ziegler R. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women: results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Res 2007; 67:1893-1897.

  328. Weitzel JN, Buys SS, Sherman WH, Daniels AM, Ursin G, Daniels JR, MacDonald DJ, Blazer KT, Pike MC, Spicer DV. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007; 13:654-658.

  329. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007; 165:262-270.

  330. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, Gaziano JM, Giovannucci E, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Kaaks R, Key T, Kolonel LN, Kraft P, Le Marchand L, Ma J, Pike MC, Riboli E, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Virtamo J, Andriole G, Gelmann E, Willett WC, Hunter DJ. A Common 8q24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study. Cancer Res 2007; 67:2951-2956.

  331. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, Dicioccio R, McGuire V, Webb PM, Beesley J, Green AC, Whiteman DC, Goodman MT, Lurie G, Carney ME, Modugno F, Ness RB, Edwards RP, Moysich KB, Goode EL, Couch FJ, Cunningham JM, Sellers TA, Wu AH, Pike MC, Iversen ES, Marks JR, Garcia-Closas M, Brinton L, Lissowska J, Peplonska B, Easton DF, Jacobs I, Ponder BA, Schildkraut J, Pearce CL, Chenevix-Trench G, Berchuck A, Pharoah PD. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007; 67:3027-3035.

  332. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolonel LN, Frasco M, Wong D, Pooler LC, Ardlie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Altshuler D, Henderson BE, Reich D. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39:638-644.

  333. Chen Y-C, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burtt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano M, Giovannucci E, Sanchez MJ, Haiman A, Hallmans G, Hayes RB, Henderson BE, Hirschhorn JH, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, Palli D, Pharaoh P, Pike MC, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ. Sequence variants of estrogen receptor B and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomark Prev 2007; 16:1971-1981.

  334. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 2007; 166:1150-1158.

  335. Monroe KR, Murphy SP, Kolonel LN, Pike MC. Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. Br J Cancer 2007; 97:440-445.

  336. Roddam AW, Pirie K, Pike MC, Chilvers C, Crossley B, Hermon C, McPherson K, Peto J, Vessey M, Beral V. Active and passive smoking and the risk of breast cancer in women aged 36-45 years: a population based case-control study in the UK. Br J Cancer 2007; 3:434-439.

  337. Nomura AM, Hankin JH, Henderson BE, Wilkens LR, Murphy SP, Pike MC, Le Marchand L, Stram DO, Monroe KR, Kolonel LN. Dietary fiber and colorectal cancer risk: the Multiethnic Cohort Study. Cancer Causes Control 2007; 7:753-764.

  338. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, Doerge DR. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol 2007; 21:3024-3030.

  339. Weitzel JN, Buys SS, Sherman WH, Daniels A, Ursin G, Daniels JR, MacDonald DJ, Blazer KR, Pike MC, Spicer DV. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007; 13:654-658.

  340. Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis 2007; 7:1561-1566.

  341. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the Multiethnic Cohort. BMC Med Genet 2007; 8:72.

  342. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn J, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, Palli D, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis R, Trichopoulos D, Yeager M, Ziegler RG, Spencer Feigelson H, Chanock SJ. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomark Prev 2007; 16:2237-2246.

  343. Monroe KR, Murphy SP, Henderson BE, Kolonel LN, Stanczyk FZ, Adlercreutz H, Pike MC. Dietary fiber intake and endogenous serum hormone levels in naturally postmenopausal Mexican American women: the Multiethnic Cohort Study. Nutr Cancer 2007; 58:127-35.

  344. Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, Kolonel LN, Henderson BE. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet. 2008; 17:2456-2461.

  345. Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer 2008; 123:380-388.

  346. Henderson KD, Bernstein L, Henderson B, Kolonel L, Pike MC. Predictors of the timing of natural menopause in the Multiethnic Cohort Study. Am J Epidemiol 2008; 167:1287-1294.

  347. Stuedal A, Ma H, Bernstein L, Pike MC, Ursin G. Does breast size modify the association between mammographic density and breast cancer risk? Cancer Epidemiol Biomark Prev 2008;17:621-627.

  348. Pearce CL, Near AM, Butler JL, Van Den Berg D, Bretsky P, Conti DV, Stram DO, Pike MC, Hirschhorn JN, Wu AH. Comprehensive evaluation of ESR2 variation and ovarian cancer risk. Cancer Epidemiol Biomark Prev 2008;17:393-396.

  349. Pearce CL, Wu AH, Gayther SA, Bale AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A; Ovarian Cancer Association Consortium. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 2008; 98:282-288.

  350. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Van Den Berg DJ, Hamilton AS, Deapen DM, Mack TM. Interleukin-2, interleukin-12, and interferon-gamma levels and risk of young adult Hodgkin lymphoma. Blood 2008; 111:3377-3382.

  351. Nomura AM, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Pike MC, Kolonel LN. Association of vegetable, fruit, and grain intakes with colorectal cancer: the Multiethnic Cohort Study. Am J Clin Nutr 2008; 88:730-737.

  352. Wu AH, Yu MC, Tseng C-C, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008; 98:9-14.

  353. Collaborative Group on Epidemiological Studies of Ovarian Cancer (Pike MC, member). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet 2008; 371:303-314.

  354. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 2008; 3:e2578.

  355. Setiawan VW, Monroe KR, Goodman MT, Kolonel LN, Pike MC, Henderson BE. Alcohol consumption and endometrial cancer risk: the multiethnic cohort. Int J Cancer 2008; 122:634-638.

  356. Cox DG, Bretsky P, Kraft P, Pharoah P, Albanes D, Altshuler D, Amiano P, Berglund G, Boeing H, Buring J, Burtt N, Calle EE, Canzian F, Chanock S, Clavel-Chapelon F, Colditz GA, Feigelson HS, Haiman CA, Hankinson SE, Hirschhorn J, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, LeMarchand L, Lund E, Palli D, Peeters PH, Pike MC, Riboli E, Stram DO, Thun M, Tjonneland A, Travis RC, Trichopoulos D, Yeager M. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer 2008; 122:387-392.

  357. Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Vandenberg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas, A, Berchuck A, Schildkraut JM. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008; 17:3567-3572.

  358. Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Dietary patterns and breast cancer risk in Asian American women. Am J Clin Nutr 2009; 89:1145-1154.

  359. Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, Bartow S, Pike MC, Wu AH, Hawes D. Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Res Treat 2009; Epub 10 Feb.

  360. Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata D, Conti DV, Yuan JM, Pike MC, Gago-Dominguez M. Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer 2009; 100:834-839.

  361. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009; 115:531-539.

  362. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009; 124:1409-1415.

  363. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the Multiethnic Cohort Study. Am J Epidemiol 2009; 169:1251-1259.

  364. Korde LA, Wu AH, Fears T, Nomura AM, West DW, Kolonel LN, Pike MC, Hoover RN, Ziegler RG; Childhood soy intake and breast cancer risk in Asian American women. Cancer Epidemiol Biomarkers Prev 2009; 18: 1050-1059.

  365. Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Hogdall E, DiCioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Hogdall C, Blaakaer J, Easton DF, Ponder BA, Jacobs IJ, Menon U, Whittemore AS, Kruger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 2009; 100: 993-1001.

  366. Edwards QT, Li AX, Pike MC, Kolonel LN, Ursin G, Henderson BE, McKean-Cowdin R; Ethnic differences in the use of regular mammography: the Multiethnic Cohort. Breast Cancer Res Treat. 2009; 115:163-170.

  367. [PubMed Abstract]

    Stone J, Folkerd E, Doody D, Schroen C, Treloar SA, Giles GG, Pike MC, English DR, Southey MC, Hopper JL, Dowsett M. Familial correlations in postmenopausal serum concentrations of sex steroid hormones and other mitogens: a twins and sisters study. J Clin Endocrinol Metab 2009; 94:4793-4800.

  368. [PubMed Abstract]

    Stern MC, Van Den Berg D, Yuan JM, Conti DV, Gago-Dominguez M, Pike MC, Xiang YB, Gao YT, Cortessis VK. Sequence variant on 3q28 and urinary bladder cancer risk: findings from the Los Angeles-Shanghai bladder case-control study. Cancer Epidemiol Biomarkers Prev 2009; 18:3057-3061.

  369. [PubMed Abstract]

    Brown LM, Gridley G, Wu AH, Falk RT, Hauptmann M, Kolonel LN, West DW, Nomura AM, Pike MC, Hoover RN, Ziegler RG. Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women. Breast Cancer Res Treat 2010; 120:203-210.

  370. [PubMed Abstract]

    Woolcott CG, Maskarinec G, Pike MC, Henderson BE, Wilkens LR, Kolonel LN. Breast cancer risk and hysterectomy status: the Multiethnic Cohort study. Cancer Causes Control 2009; 20:539-547.

  371. [PubMed Abstract]

    Johnatty SE, Beesley J, Chen X, … Pike M, … Chenevix-Trench G. Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. Twin Res Hum Genet 2009; 12:269-275.

  372. [PubMed Abstract]

    Phelan CM, Tsai YY, Goode EL, … Pike MC, … Australian Ovarian Cancer Study Group. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010; 19:600-604.

  373. [PubMed Abstract]

    Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009; 26:1-27.

  374. [PubMed Abstract]

    Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475-83.

  375. [PubMed Abstract]

    Doherty JA, Rossing MA, Cushing-Haugen KL, … Pike MC, … Ovarian Cancer Association Consortium (OCAC). ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers Prev. 2010;19:245-50.

  376. [PubMed Abstract]

    Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L. Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res. 2010;70:221-228.

  377. [PubMed Abstract]

    Johnatty SE, Beesley J, Chen X, …Pike MC, … Ovarian Cancer Association Consortium. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility “hot-spot”. PLoS Genetics. 2010;6:e1001016.

  378. [PubMed Abstract]

    Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral comtraceptive in obese and normal weight women. Contraception. 2010;81:474-480.

  379. [PubMed Abstract]

    Edwards QT, Li A, Pike MC, Kolonel L, Henderson BE, McKean-Cowdin R. Patterns of regular use of mammography - body weight and ethnicity: the Multiethnic Cohort. J Am Acad Nurse Pract. 2010;22:162-169.

  380. [PubMed Abstract]

    Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA, Schwartz AM, Slomski C, Yothers G, Zon R. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 2010; 102:161-9.

  381. [PubMed Abstract]

    Gago-Dominguez M, Jiang X, Conti DV, Castelao JE, Stern MC, Cortessis VK, Pike MC, Xiang YB, Gao YT, Yuan JM, Van Den Berg D. Genetic Variations on Chromosomes 5p15 and 15q25 and Bladder Cancer Risk: Findings from the Los Angeles-Shanghai Bladder Case-Control Study. Carcinogenesis. 2010; [Epub ahead of print].

  382. [PubMed Abstract]

    Cortessis VK, Yuan JM, Van Den Berg D, Jiang X, Gago-Dominguez M, Stern MC, Castelao JE, Xiang YB, Gao YT, Pike MC, Conti DV. Risk of urinary bladder cancer is associated with 8q24 Variant rs9642880[T]: Results from the Los Angeles-Shanghai Case-Control Study. Cancer Epidemiol Biomarkers Prev 2010; [Epub ahead of print].

  383. [PubMed Abstract]

    Rothman N, Garcia-Closas M, Chatterjee N,…Pike MC,…et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010;42:978-84.

  384. [PubMed Abstract]

    Goode EL, Chenevix-Trench G, Song H, …Pike MC… Ovarian Cancer Association Consortium (OCAC). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010; 42:874-9.

  385. [PubMed Abstract]

    Jiang X, Castelao JE, Yuan JM, Groshen S, Stern MC, Conti DV, Cortessis VK, Coetzee GA, Pike MC, Gago-Dominguez M. Hypertension, diuretics andantihypertensives in relation to bladder cancer. Carcinogenesis 2010; 31:1964-71.

  386. [PubMed Abstract]

    Near AM, Wu AH, Templeman C, Van Den Berg DJ, … Pike MC, …, Ovarian Cancer Association Consortium. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril 2010; [Epub ahead of print].

  387. [PubMed Abstract]

    Notaridou M, Quaye L, Dafou D, Pike MC, … Ovarian Cancer Association Consortium. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer. 2010; [Epub ahead of print].

  388. [PubMed Abstract]

    King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA.  Background parenchymal enhancement at breast MR imaging and breast cancer risk.  Radiology 2011; 260:50-60.

  389. [PubMed Abstract]

    Lurie G, Wilkens LR, Thompson PJ, … Pike MC, … et al.  Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: Pooled analysis within the Ovarian Cancer Association Consortium.  PLoS One 2011; 6:e20703.

  390. [PubMed Abstract]

    Davis-Dao CA, Siegmund KD, Vandenberg DJ, Skinner EC, Coetzee GA, Thomas DC, Pike MC, Cortessis VK.  Heterogeneous effect of androgen receptor CAG tract length on testicular germ cell tumor risk: shorter repeats associated with seminoma but not other histologic types.  Carcinogenesis 2011; E pub.

  391. [PubMed Abstract]

    Wu AH, Yu MC, Stanczyk FZ, Tseng CC, Pike MC.  Anthropometric, dietary, and hormonal correlates of serum adiponectin in Asian American women. Nutr Cancer 2011; 63: 549-557.

  392. [PubMed Abstract]

    Davis-Dao CA, Henderson KD, Sullivan-Halley J, Ma H, West D, Xiang YB, Gago-Dominguez M, Stern MC, Castelao JE, Conti DV, Pike MC, Bernstein L, Cortessis VK.  Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology.  Cancer Epidemiol Biomarkers Prev 2011; 20: 1156-1170.

  393. [PubMed Abstract]

    Pearce CL, Doherty JA, Vandenberg DJ, … Pike MC, … et al.  Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet 2011; 20: 2263-2272.

  394. [PubMed Abstract]

    Amankwah EK, Kelemen LE, Wang Q, … Pike MC, … et al.  Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer.  Cancer Epidemiol Biomarkers Prev 2011; 20: 1028-1031.

  395. [PubMed Abstract]

    Pharoah PD, Palmieri RT, Ramus SJ, … Pike MC, … et al.  The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.  Clin Cancer Res 2011; 17:3742-3750.

  396. [PubMed Abstract]

    Notaridou M, Quaye L, Dafou D, … Pike MC, … et al.  Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.  Int J Cancer 2011; 128: 2063-2074.

  397. [PubMed Abstract]

    Liu L, Zhang J, Wu AH, Pike MC, Deapen D.  Invasive breast cancer incidence trends by detailed race/ethnicity and age.  Int J Cancer 2012; 130: 395-404.

  398. [PubMed Abstract]

    Lurie G, Gaudet MM, Spurdie AB, … Pike MC, … et al.  The obesity associated polymorphisms FTO rs9939609 and MCR rs17782313 and endometrial cancer risk in non-Hispanic white women.  PLoS One 2011; 6:e16756.

  399. [PubMed Abstract]

    Rothman N, Garcia-Closas M, Chatterjee N, …Pike MC, … et al.  A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.  Nat Genet 2011; 42: 978-984.

  400. Formenti SC, Arslan AA, Pike MC:  Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.  J Natl Cancer Inst 2011; 103: 1723.

  401. [PubMed Abstract]

    Davis-Dao C, Koh CJ, Hardy BE, … Pike MC, … Cortessis VK.  Shorter androgen receptor CAG repeat lengths associated with cryptorchidism risk among Hispanic white boys.  J Clin Endocrinol Metab 2012; 97:E393-399.

  402. [PubMed Abstract]

    Jiang X, Castelao JE, Yuan JM, … Pike MC, Gago-Dominguez M.  Cigarette smoking and subtypes of bladder cancer.  Int J Cancer 2012; 130:896-901.  

  403. [PubMed Abstract]

    Westhoff CL, Torgal AT, Mayeda ER, Shimoni N, Stanczyk FZ, Pike MC.  Predictors of noncompliance in an oral contraceptive clinical trial.  Contraception 2012; 85:465-469.

  404. [PubMed Abstract]

    King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA.  Background parenchymal enhancement at breast MR imaging and breast cancer risk.  Radiology 2011; 260:50-60.

  405. [PubMed Abstract]

    Chung K, Hovanessian-Larsen LJ, … Pike MC, … Pearce CL.  Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.  Breast Cancer Res Treat 2012; 132:653-660.

  406. [PubMed Abstract]

    Hovanessian-Larsen L, Taylor D, … Pike MC, Pearce CL.  Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.  Contraception 2012; 86:238-243.

  407. [PubMed Abstract]

    King V, Gu Y, Kaplan JB, Brooks JD, Pike MC, Morris EA.  Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.  Eur Radiol 2012; 22:2641-2647.

  408. [PubMed Abstract]

    King V, Goldfarb SB, Brooks JD, …Pike MC, … Morris EA.  Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MRI imaging.  Radiol 2012; 264:670-678.

  409. [PubMed Abstract]

    King V, Kaplan J, Pike MC, … Morris EA.  Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.  Breast J 2012; 18:527-534.

  410. [PubMed Abstract]

    Clendenen TV, Kim S, Moy L, Wan L, Rusinek H, Stanczyk FZ, Pike MC, Zeleniuch-Jacquotte A.  Magnetic resonance imaging (MRI) of hormone-induced breast changes in young premenopausal women.  Magn Reson Imaging 2013; 31:1-9.

  411. [PubMed Abstract]

    Reiner AS, John EM, Brooks JD, … Pike MC, … Bernstein J.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study.  J Clin Oncol 2012; [Epub ahead of print]  

  412. [PubMed Abstract]

    Collaborative Group on Epidemiological Studies of Ovarian Cancer.  Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies.  Lancet Oncol 2012; 13:946-956.

  413. [PubMed Abstract]

    Setiawan VW, Pike MC, Karageorgi S, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium.  Am J Epidemiol 2012;176:269-278.

  414. [PubMed Abstract]

    Wu AH, Spicer DV, Pike MC.  Soy isoflavones for breast cancer risk reduction.  Cancer Prev Res 2012; 5:984-985; author reply 986-987.

  415. [PubMed Abstract]

    Begg CB, Pike MC.  Comment on “the predictive capacity of personal genome sequencing”.  Sci Transl Med 2012; 4:135le3.

  416. [PubMed Abstract]

    Yen HY, Gabet Y, Liu Y, … Pike MC, et al.  Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab Invest 2012; 92:802-811.

  417. [PubMed Abstract]

    Pearce CL, Templeman C, Rossing MA, … Pike MC, … Ovarian Cancer Association Consortium.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.  Lancet Oncol 2012; 13:385-394.

  418. [PubMed Abstract]

    Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC.  Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women.  Cancer Prev Res 2012; 5:393-402.

  419. [PubMed Abstract]

    Plummer M, Peto J, Franceschi S, … Pike MC, … International Collaboration of Epidemiological Studies of Cervical Cancer.  Time since first sexual intercourse and the risk of cervical cancer.  Int J Cancer 2012;130:2638-2644.